There are certain adjustments that CMS can make to Oncology Care First (OCF) during the delay that CMS is already doing successfully in other alternative payment models, said Mike Fazio, at Archway Health.
There are certain adjustments that CMS can make to Oncology Care First (OCF) during the delay that CMS is already doing successfully in other alternative payment models, said Mike Fazio, senior vice president of Client Services at Archway Health.
Transcript
Given the delayed start to Oncology Care First, where do you see opportunities for CMS to make changes to the model based on the ongoing challenges practices may have reported with the Oncology Care Model?
So, you know, we provided feedback back when they had an open period for comments, and I haven't seen anything come out of CMMI [Center for Medicare and Medicare Innovation] or CMS related to what changes they possibly could make to OCF. So, we've just been—as we communicate with CMS in both OCM [Oncology Care Model] and other programs—we've been trying to hit home adjustments that we'd like to see in the model that we hear from customers. But a lot of what we recommended were based on the other programs that they run, so specifically BPCI [Bundled Payments for Care Improvement] Advanced.
And so, a big one was the way that they created the regression model for OCM, which was really all cancer types. And so, what we see with BPCI Advanced is they look at each bundle individually and come up with pricing by bundle instead of the totality of all bundles that a program entails. And so those types of things, which really get into the pricing, is what we emphasized and said borrow what worked or is working in these other pilots. And that's what we expect to see with OCF. And we haven't seen details yet, if those things will be adjusted.
So, it sounded really good. You know, what we did take away from what CMS was indicating would be part of this new model. We haven't seen what that pricing model will be or how baseline or benchmarks will be created. And so, I guess those are big parts that we still need to see and hear. And we think that CMS is working on refining that and taking comments seriously. But I guess the proof will be once we get our hands on the pricing specs in the baseline data in benchmarks if they will be using for OCF.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More